Hospital
William Beaumont Hospital
William Beaumont Hospital was paid $84.88M by Medicaid between Jan 2018 and Dec 2024, across 561 billing codes. Its largest line is 99285, emergency room visit (most serious) — 31% of everything it billed.
33Billing provider infoWILLIAM BEAUMONT HOSPITAL
TROY, MI 48085
TROY, MI 48085
33aNPI1306825997assigned 01/11/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$84.88M
24GClaims2,438,910
24DCodes billed561
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#12 of 86
Median peer was paid$21.55M
This provider vs. median3.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official COX, MATTHEW controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 220,857 | $9.17M | |
| 2019 | 355,510 | $9.98M | |
| 2020 | 290,525 | $9.58M | |
| 2021 | 356,610 | $12.67M | |
| 2022 | 403,730 | $15.42M | |
| 2023 | 435,670 | $15.93M | |
| 2024incomplete | 376,008 | $12.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 31% | 64,833 | 60,613 | $26.71M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.0% | 34,124 | 33,103 | $7.65M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 7.2% | 84,281 | 77,530 | $6.14M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.4% | 35,301 | 33,055 | $2.88M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 3.4% | 7,092 | 7,072 | $2.87M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.3% | 19,864 | 19,269 | $2.83M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.9% | 2,936 | 2,927 | $1.61M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 9,087 | 8,966 | $1.12M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 5,646 | 5,631 | $1.09M |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 23,339 | 22,815 | $968K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.1% | 39,591 | 10,750 | $930K |
| 80061 | Lipid panel | 1.0% | 42,146 | 41,949 | $865K |
549 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.0% | 46,419 | $856K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,814 | $827K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 20,406 | $795K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 15,496 | $737K |
| 93975 | <1% | 6,922 | $736K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 19,047 | $721K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 19,606 | $636K |
| 82947 | <1% | 15,721 | $604K | |
| G0378 | Hospital observation service, per hour | <1% | 18,724 | $576K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 9,002 | $550K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 26,434 | $545K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,977 | $528K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,125 | $527K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 8,064 | $519K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 5,048 | $484K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 29,106 | $478K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,478 | $447K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 5,433 | $443K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 48,202 | $414K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 829 | $411K |
| 76830 | Ultrasound, transvaginal | <1% | 7,174 | $404K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,450 | $401K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 10,355 | $398K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 8,707 | $397K |
| 62323 | <1% | 1,220 | $382K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 918 | $370K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 25,897 | $370K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 836 | $362K |
| 80053 | Comprehensive metabolic panel | <1% | 102,664 | $358K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,447 | $347K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 2,504 | $323K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 3,208 | $301K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 413 | $300K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,318 | $285K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 3,750 | $277K |
| 76770 | <1% | 4,621 | $274K | |
| 97162 | <1% | 4,687 | $263K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,280 | $261K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,737 | $258K |
| 47562 | <1% | 74 | $257K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 123,553 | $230K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 13,212 | $227K |
| 59025 | Fetal non-stress test | <1% | 2,684 | $225K |
| 76536 | <1% | 4,320 | $218K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12,819 | $213K |
| 76801 | <1% | 3,615 | $202K | |
| 74183 | <1% | 1,116 | $193K | |
| 72141 | <1% | 1,571 | $190K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,963 | $189K |
| 76642 | <1% | 4,770 | $189K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,069 | $181K |
| 73221 | <1% | 1,354 | $179K | |
| 19083 | <1% | 222 | $177K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 35,202 | $174K |
| 93971 | <1% | 3,262 | $169K | |
| 77066 | Tomosynthesis, mammo | <1% | 2,897 | $164K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,069 | $156K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,634 | $155K |
| 77065 | Tomosynthesis, mammo | <1% | 3,490 | $151K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 15,187 | $148K |
| 82607 | <1% | 18,910 | $144K | |
| 71250 | <1% | 2,291 | $131K | |
| 77080 | <1% | 2,237 | $129K | |
| 93970 | <1% | 1,289 | $125K | |
| 86003 | <1% | 2,633 | $122K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 9,464 | $117K |
| 72110 | <1% | 4,791 | $117K | |
| 84466 | <1% | 15,587 | $105K | |
| 90651 | <1% | 913 | $103K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 7,084 | $101K |
| 95811 | <1% | 207 | $99K | |
| 74178 | <1% | 565 | $97K | |
| 82728 | <1% | 14,302 | $96K | |
| 93350 | <1% | 428 | $95K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,077 | $93K |
| 87631 | <1% | 7,250 | $91K | |
| 97161 | <1% | 1,766 | $90K | |
| 84439 | <1% | 19,049 | $89K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 41,722 | $88K |
| 80074 | <1% | 3,865 | $88K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 8,990 | $88K |
| 90670 | <1% | 1,503 | $87K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 5,287 | $85K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 7,104 | $85K |
| 82746 | <1% | 10,256 | $82K | |
| 90686 | <1% | 5,403 | $79K | |
| 84481 | <1% | 8,250 | $77K | |
| 97116 | <1% | 7,180 | $77K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,601 | $73K |
| 85027 | <1% | 32,441 | $73K | |
| 93880 | <1% | 991 | $72K | |
| 86480 | <1% | 1,942 | $71K | |
| 73564 | <1% | 3,354 | $70K | |
| 74019 | <1% | 3,721 | $67K | |
| 97166 | <1% | 1,371 | $66K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 95,042 | $61K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 24,756 | $61K |
| 70486 | <1% | 1,424 | $59K | |
| 87480 | <1% | 5,411 | $59K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 995 | $59K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,374 | $59K |
| 83013 | <1% | 1,414 | $56K | |
| 74018 | <1% | 2,771 | $56K | |
| 83540 | <1% | 16,149 | $55K | |
| 86900 | <1% | 10,200 | $55K | |
| 87660 | <1% | 5,150 | $55K | |
| 93017 | <1% | 3,179 | $55K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,871 | $53K |
| 87510 | <1% | 5,010 | $52K | |
| 71271 | <1% | 935 | $51K | |
| 84403 | <1% | 3,213 | $49K | |
| 83970 | <1% | 2,240 | $48K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,801 | $47K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,528 | $45K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,073 | $45K |
| 90750 | <1% | 309 | $44K | |
| 94726 | <1% | 947 | $43K | |
| 84702 | <1% | 26,732 | $43K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 33,375 | $42K |
| 90732 | <1% | 407 | $40K | |
| 86803 | <1% | 4,855 | $39K | |
| 73030 | <1% | 2,982 | $39K | |
| 94060 | <1% | 257 | $36K | |
| 73630 | <1% | 3,412 | $36K | |
| 92523 | <1% | 315 | $35K | |
| 90677 | <1% | 200 | $34K | |
| 82670 | <1% | 2,027 | $32K | |
| 73610 | <1% | 2,915 | $32K | |
| 73130 | <1% | 2,625 | $32K | |
| 86038 | <1% | 4,862 | $31K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 14,497 | $30K |
| 86780 | <1% | 3,171 | $30K | |
| 82784 | <1% | 3,783 | $29K | |
| 83001 | <1% | 2,596 | $27K | |
| 72070 | <1% | 1,277 | $27K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 455 | $26K |
| 44970 | <1% | 12 | $25K | |
| 84550 | <1% | 10,305 | $25K | |
| 73502 | <1% | 1,989 | $25K | |
| 97165 | <1% | 582 | $25K | |
| 82785 | <1% | 2,682 | $24K | |
| 84146 | <1% | 2,218 | $24K | |
| 84153 | <1% | 2,556 | $24K | |
| 86696 | <1% | 2,186 | $24K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,387 | $24K |
| 83735 | <1% | 19,737 | $24K | |
| 10005 | <1% | 67 | $23K | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 1,068 | $23K |
| 73110 | <1% | 2,090 | $22K | |
| 83002 | <1% | 2,111 | $22K | |
| 72050 | <1% | 444 | $22K | |
| 86352 | <1% | 279 | $21K | |
| 86376 | <1% | 2,590 | $21K | |
| 86769 | <1% | 1,038 | $20K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,428 | $20K |
| 84402 | <1% | 1,409 | $20K | |
| 72052 | <1% | 519 | $20K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 1,304 | $19K |
| 70491 | <1% | 195 | $19K | |
| 87632 | <1% | 636 | $19K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,620 | $19K |
| 86140 | <1% | 9,505 | $18K | |
| 87186 | <1% | 5,747 | $18K | |
| 87077 | <1% | 5,723 | $18K | |
| 83880 | <1% | 4,015 | $17K | |
| 76881 | <1% | 302 | $17K | |
| 87340 | <1% | 3,431 | $17K | |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | <1% | 39 | $17K |
| 73562 | <1% | 851 | $17K | |
| 83516 | <1% | 2,666 | $17K | |
| 86160 | <1% | 1,250 | $16K | |
| 85610 | <1% | 14,205 | $16K | |
| 86695 | <1% | 2,186 | $16K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 230 | $16K |
| 74022 | <1% | 2,169 | $16K | |
| 17110 | <1% | 176 | $16K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 223 | $15K |
| 71101 | <1% | 812 | $15K | |
| 80076 | <1% | 5,103 | $15K | |
| 83655 | <1% | 2,369 | $15K | |
| 91322 | <1% | 109 | $15K | |
| 83993 | <1% | 1,400 | $15K | |
| 73590 | <1% | 1,574 | $15K | |
| 86800 | <1% | 1,642 | $15K | |
| 86235 | <1% | 704 | $14K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,698 | $14K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 976 | $14K |
| 84144 | <1% | 1,120 | $14K | |
| 87070 | <1% | 5,037 | $14K | |
| 88184 | <1% | 336 | $14K | |
| 81003 | <1% | 27,177 | $13K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,172 | $13K |
| 82043 | <1% | 4,490 | $13K | |
| 82627 | <1% | 1,034 | $13K | |
| 82248 | <1% | 6,953 | $13K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 289 | $12K |
| 81001 | <1% | 22,534 | $12K | |
| 97163 | <1% | 204 | $12K | |
| 86850 | <1% | 9,753 | $12K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 170 | $12K |
| 87427 | <1% | 1,344 | $12K | |
| 86762 | <1% | 1,580 | $11K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 52 | $11K |
| 86147 | <1% | 271 | $11K | |
| 82570 | <1% | 4,854 | $11K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 660 | $11K |
| 80069 | <1% | 2,561 | $11K | |
| 81025 | <1% | 9,040 | $11K | |
| 87046 | <1% | 1,434 | $11K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 860 | $10K |
| 86592 | <1% | 3,227 | $10K | |
| 82550 | <1% | 5,658 | $10K | |
| 83021 | <1% | 1,042 | $10K | |
| 49083 | <1% | 21 | $10K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 13 | $10K |
| 85652 | <1% | 8,961 | $10K | |
| 10060 | <1% | 125 | $10K | |
| 82533 | <1% | 1,075 | $10K | |
| 83690 | <1% | 21,688 | $10K | |
| 87147 | <1% | 3,166 | $9K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,540 | $9K |
| 82565 | <1% | 3,861 | $9K | |
| 84445 | <1% | 260 | $9K | |
| 87653 | <1% | 714 | $9K | |
| 76870 | <1% | 986 | $9K | |
| 78227 | <1% | 40 | $9K | |
| 86787 | <1% | 1,211 | $9K | |
| 96367 | <1% | 719 | $9K | |
| 82105 | <1% | 1,012 | $9K | |
| 82247 | <1% | 3,914 | $9K | |
| 72100 | <1% | 284 | $8K | |
| 86200 | <1% | 1,078 | $8K | |
| 86706 | <1% | 1,461 | $8K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 76 | $8K |
| 85730 | <1% | 8,501 | $8K | |
| 73080 | <1% | 896 | $8K | |
| 81514 | <1% | 42 | $7K | |
| 87338 | <1% | 987 | $7K | |
| 84100 | <1% | 6,965 | $7K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 103 | $7K |
| 90837 | Psychotherapy session, about an hour | <1% | 89 | $7K |
| 86225 | <1% | 932 | $7K | |
| 90739 | <1% | 56 | $7K | |
| 73090 | <1% | 1,212 | $7K | |
| 90716 | <1% | 185 | $7K | |
| 75574 | <1% | 90 | $7K | |
| 87428 | <1% | 353 | $7K | |
| 84425 | <1% | 556 | $7K | |
| 84520 | <1% | 3,483 | $6K | |
| 90734 | <1% | 275 | $6K | |
| 73140 | <1% | 353 | $6K | |
| 86431 | <1% | 2,061 | $6K | |
| 83615 | <1% | 3,046 | $6K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 196 | $6K |
| 84165 | <1% | 1,222 | $6K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 88 | $6K |
| 82378 | <1% | 599 | $6K | |
| 90474 | <1% | 1,124 | $6K | |
| 84460 | <1% | 2,708 | $6K | |
| 88342 | <1% | 1,470 | $6K | |
| 84450 | <1% | 3,280 | $6K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 85 | $6K |
| 82465 | <1% | 1,053 | $6K | |
| 0124A | <1% | 184 | $5K | |
| 83525 | <1% | 826 | $5K | |
| 70360 | <1% | 356 | $5K | |
| 86300 | <1% | 412 | $5K | |
| 87209 | <1% | 683 | $5K | |
| 86146 | <1% | 196 | $5K | |
| 87522 | Neg quan hep c or qual rna | <1% | 236 | $5K |
| 77336 | <1% | 76 | $5K | |
| 86665 | <1% | 399 | $5K | |
| 82652 | <1% | 224 | $5K | |
| 86162 | <1% | 366 | $5K | |
| 80305 | <1% | 1,106 | $5K | |
| 87045 | <1% | 1,411 | $5K | |
| 82274 | <1% | 601 | $4K | |
| 84432 | <1% | 425 | $4K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,262 | $4K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 12 | $4K |
| 86704 | <1% | 653 | $4K | |
| 85379 | <1% | 4,566 | $4K | |
| 86039 | <1% | 769 | $4K | |
| 90671 | <1% | 110 | $4K | |
| 82950 | <1% | 1,636 | $4K | |
| 90480 | <1% | 110 | $4K | |
| 82150 | <1% | 2,182 | $4K | |
| 72040 | <1% | 234 | $4K | |
| 80197 | <1% | 477 | $4K | |
| 84156 | <1% | 2,610 | $4K | |
| 87634 | <1% | 112 | $4K | |
| 10022 | <1% | 17 | $4K | |
| 98929 | <1% | 319 | $4K | |
| 86901 | <1% | 9,667 | $4K | |
| 0054A | <1% | 111 | $4K | |
| 84478 | <1% | 120 | $4K | |
| 96376 | <1% | 13,994 | $3K | |
| 90656 | <1% | 217 | $3K | |
| 88304 | <1% | 2,039 | $3K | |
| 36430 | <1% | 28 | $3K | |
| 87449 | <1% | 912 | $3K | |
| 73523 | <1% | 62 | $3K | |
| 72131 | <1% | 81 | $3K | |
| 87324 | <1% | 822 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 266 | $3K |
| 73700 | <1% | 52 | $3K | |
| 86334 | <1% | 289 | $3K | |
| 80051 | <1% | 1,215 | $3K | |
| 82977 | <1% | 723 | $3K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 71 | $3K |
| 86256 | <1% | 249 | $3K | |
| 84484 | <1% | 23,535 | $3K | |
| 87177 | <1% | 683 | $3K | |
| 80050 | General health panel | <1% | 194 | $3K |
| 0004A | <1% | 73 | $3K | |
| 72197 | <1% | 13 | $2K | |
| 84134 | <1% | 397 | $2K | |
| 84630 | <1% | 402 | $2K | |
| 20610 | <1% | 15 | $2K | |
| 80081 | <1% | 74 | $2K | |
| 85046 | <1% | 1,268 | $2K | |
| 95816 | <1% | 24 | $2K | |
| 88185 | <1% | 87 | $2K | |
| 82040 | <1% | 1,547 | $2K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 175 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 16,307 | $2K |
| 70496 | <1% | 54 | $2K | |
| 87328 | <1% | 298 | $2K | |
| 86304 | <1% | 197 | $2K | |
| 76882 | <1% | 40 | $2K | |
| 87329 | <1% | 331 | $2K | |
| 81002 | <1% | 1,880 | $2K | |
| 87205 | <1% | 2,352 | $2K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 28 | $2K |
| 77300 | <1% | 12 | $2K | |
| 86664 | <1% | 298 | $2K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 3,182 | $2K |
| 76641 | <1% | 30 | $2K | |
| 86364 | <1% | 264 | $2K | |
| 84305 | <1% | 151 | $1K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 30 | $1K |
| 74174 | <1% | 12 | $1K | |
| 86663 | <1% | 298 | $1K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 29 | $1K |
| 82525 | <1% | 216 | $1K | |
| 87641 | <1% | 102 | $1K | |
| 82310 | <1% | 696 | $1K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 33 | $1K |
| 84075 | <1% | 797 | $1K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,503 | $1K |
| 88312 | <1% | 1,005 | $1K | |
| 87081 | <1% | 388 | $1K | |
| 86255 | <1% | 155 | $1K | |
| 99385 | <1% | 17 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 40 | $1K |
| 90746 | <1% | 16 | $1K | |
| 83090 | <1% | 117 | $983.79 | |
| 87640 | <1% | 75 | $982.10 | |
| 94010 | <1% | 139 | $926.38 | |
| 87040 | <1% | 1,828 | $851.60 | |
| 88112 | <1% | 119 | $809.10 | |
| 72146 | <1% | 13 | $775.26 | |
| 82962 | <1% | 3,194 | $768.64 | |
| 0001A | <1% | 20 | $763.04 | |
| 97014 | <1% | 86 | $753.07 | |
| 0002A | <1% | 19 | $719.15 | |
| 73552 | <1% | 98 | $691.45 | |
| 90647 | <1% | 1,073 | $691.20 | |
| 12011 | <1% | 444 | $684.89 | |
| 73060 | <1% | 157 | $683.94 | |
| 82951 | <1% | 96 | $683.18 | |
| 88307 | <1% | 173 | $677.21 | |
| 98928 | <1% | 54 | $666.98 | |
| 86005 | <1% | 62 | $638.82 | |
| 72082 | <1% | 12 | $618.84 | |
| 96127 | <1% | 101 | $606.10 | |
| 70498 | <1% | 36 | $598.91 | |
| 85018 | <1% | 2,096 | $589.72 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 23 | $563.76 |
| 84155 | <1% | 585 | $557.16 | |
| 86308 | <1% | 1,533 | $554.42 | |
| 88341 | <1% | 253 | $549.72 | |
| 83605 | <1% | 8,351 | $524.32 | |
| 86301 | <1% | 40 | $509.15 | |
| 0052A | <1% | 13 | $487.89 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,777 | $472.31 |
| 84145 | <1% | 2,258 | $467.62 | |
| 83550 | <1% | 166 | $447.89 | |
| 98927 | <1% | 37 | $447.08 | |
| 72072 | <1% | 24 | $436.92 | |
| 86765 | <1% | 90 | $434.12 | |
| 94618 | <1% | 25 | $399.51 | |
| 82024 | <1% | 16 | $388.61 | |
| 85014 | <1% | 842 | $385.45 | |
| 12001 | <1% | 576 | $371.75 | |
| 86735 | <1% | 41 | $347.22 | |
| 83521 | <1% | 34 | $341.51 | |
| 80164 | <1% | 81 | $339.21 | |
| 84132 | <1% | 497 | $337.17 | |
| 87075 | <1% | 193 | $327.17 | |
| 82103 | <1% | 52 | $312.84 | |
| 82088 | <1% | 12 | $311.79 | |
| 84703 | <1% | 4,901 | $307.48 | |
| 82390 | <1% | 43 | $282.92 | |
| 87184 | <1% | 54 | $244.10 | |
| C1769 | Guide wire | <1% | 873 | $241.99 |
| 73000 | <1% | 24 | $237.90 | |
| G0008 | Administration of influenza virus vaccine | <1% | 52 | $237.70 |
| 83630 | <1% | 42 | $236.90 | |
| 82805 | <1% | 27 | $234.20 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 25,631 | $230.76 |
| 86141 | <1% | 32 | $230.41 | |
| 83695 | <1% | 27 | $227.20 | |
| 83010 | <1% | 55 | $215.07 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 13 | $208.30 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,250 | $201.98 |
| 89051 | <1% | 127 | $187.92 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 69 | $182.63 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 2,052 | $168.52 |
| 86215 | <1% | 17 | $151.61 | |
| 69209 | <1% | 13 | $133.94 | |
| 82952 | <1% | 62 | $131.96 | |
| 85384 | <1% | 145 | $118.28 | |
| 82140 | <1% | 42 | $118.19 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 305 | $115.18 |
| 88173 | <1% | 279 | $114.65 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 25 | $114.00 |
| J3490 | Unclassified drugs | <1% | 1,580 | $113.71 |
| 82010 | <1% | 452 | $85.84 | |
| 83930 | <1% | 321 | $74.51 | |
| 85613 | <1% | 12 | $70.50 | |
| 92250 | <1% | 13 | $64.79 | |
| 90715 | <1% | 3,195 | $61.53 | |
| 88720 | <1% | 37 | $60.50 | |
| 72170 | <1% | 29 | $59.64 | |
| 92610 | <1% | 16 | $48.91 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,325 | $41.26 |
| 82542 | <1% | 63 | $38.33 | |
| 82365 | <1% | 39 | $34.92 | |
| 88313 | <1% | 17 | $27.35 | |
| 82077 | <1% | 401 | $26.36 | |
| 87210 | <1% | 1,468 | $25.26 | |
| 85007 | <1% | 15 | $24.34 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 803 | $19.80 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 11,753 | $16.77 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 787 | $14.56 |
| 82948 | <1% | 15 | $13.28 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 592 | $12.69 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 520 | $12.67 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,927 | $11.01 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,932 | $10.10 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,996 | $9.54 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,245 | $9.38 |
| 87808 | <1% | 1,041 | $7.60 | |
| 82800 | <1% | 325 | $6.67 | |
| J2704 | Injection, propofol, 10 mg | <1% | 17,870 | $6.22 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 24,474 | $5.94 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,605 | $5.84 |
| 84295 | <1% | 16 | $5.20 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 131 | $5.10 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 8,446 | $4.94 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 224 | $4.62 |
| 93325 | <1% | 124 | $3.56 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 28,485 | $2.53 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 8,619 | $2.40 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 165 | $1.16 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 4,840 | $1.00 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,981 | $1.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,378 | $0.25 |
| 36416 | <1% | 732 | $0.10 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 4,437 | $0.01 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 283 | $0.00 |
| 94729 | 0% | 929 | $0.00 | |
| 90700 | 0% | 586 | $0.00 | |
| 90707 | 0% | 186 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 2,113 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 291 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 470 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 388 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 259 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 787 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 59 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 1,501 | $0.00 |
| 80179 | 0% | 177 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 2,169 | $0.00 |
| 90713 | 0% | 115 | $0.00 | |
| 76942 | 0% | 722 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 350 | $0.00 |
| 90633 | 0% | 562 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 807 | $0.00 |
| 80143 | 0% | 181 | $0.00 | |
| 99173 | 0% | 340 | $0.00 | |
| 91312 | 0% | 184 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 287 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 1,777 | $0.00 |
| 29125 | 0% | 39 | $0.00 | |
| 90714 | 0% | 61 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,557 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 471 | $0.00 |
| 99152 | 0% | 15 | $0.00 | |
| 93356 | 0% | 55 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 49 | $0.00 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 24 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 332 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 55 | $0.00 |
| 76125 | 0% | 17 | $0.00 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 54 | $0.00 |
| 90685 | 0% | 32 | $0.00 | |
| 91300 | 0% | 121 | $0.00 | |
| 94760 | 0% | 1,180 | $0.00 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 1,358 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 2,965 | $0.00 |
| 90680 | 0% | 964 | $0.00 | |
| A4648 | Tissue marker, implantable, any type, each | 0% | 834 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 448 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 1,015 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 589 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 378 | $0.00 |
| 94200 | 0% | 535 | $0.00 | |
| 90723 | 0% | 942 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 377 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,027 | $0.00 |
| A9573 | Injection, gadopiclenol, 1 ml | 0% | 385 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 346 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 717 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 439 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 348 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 83 | $0.00 |
| 74420 | 0% | 122 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 350 | $0.00 |
| 91305 | 0% | 225 | $0.00 | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | 0% | 13 | $0.00 |
| 84270 | 0% | 45 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 89 | $0.00 |
| 94761 | 0% | 113 | $0.00 | |
| 83520 | 0% | 52 | $0.00 | |
| 12002 | 0% | 25 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 13 | $0.00 |
| 36000 | 0% | 65 | $0.00 | |
| 90632 | 0% | 135 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 349 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,343 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 26 | $0.00 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 238 | $0.00 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | 0% | 25 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 44 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 58 | $0.00 |
| 64450 | 0% | 12 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOX, MATTHEW (CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.